secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001818382-23-000177
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte files BLA for HAV in vascular trauma; data shows superior patency and lower amputation vs synthetic grafts
--------------------------------------------------------------------------------

- BLA submitted to FDA seeking approval of Human Acellular Vessel (HAV) for urgent arterial repair in extremity vascular trauma.
- Supported by V005 Phase 2/3 trial: 90.2% 30-day secondary patency (vs 78.9% synthetic), 9.8% amputation (vs 24.3%), 2.0% infection (vs 8.4%).
- Ukraine humanitarian program (V017) data: 93.8% patency, zero amputations, zero infections; integrated analysis showed 91.5% patency, 4.5% amputation, 0.9% infection.
- Priority Review requested; FDA has RMAT designation and DoD priority for military trauma; 60-day filing review period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000177/0001818382-23-000177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000177/huma-20231212.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer